Facebook Twitter Google Plus Vimeo Youtube Feed Feedburner

Business Home LBoard

Sanofi and Lonza to build new US$285 million Swiss biologics facility

 | February 28, 2017

Sanofi, which has failed to land two big biotech acquisitions over the past year, had said it would look to strike new partnerships to spur more growth for the company.

sanofiPARIS: French drugmaker Sanofi and Swiss manufacturer Lonza will invest 270 million euros (US$285 million) in a new large-scale biologics facility that will produce monoclonal antibodies by 2020, the two companies said on Monday.

Pending regulatory approvals, the facility – which will be established through a 50-50 joint venture – will be located in Visp, Switzerland, Sanofi and Lonza said in a joint statement.

By contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in areas such as cardiovascular, neurology or cancer treatments.

Experts say they also provide means to treat a variety of medical illnesses and conditions that have no other treatments available. They are also more expensive than traditional products.

“Approximately sixty percent of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology,” said Philippe Luscan, executive vice president of global industrial affairs at Sanofi, in a statement.

“Lonza is a highly experienced partner in this field and the capabilities which this joint venture will create are critical to meeting our patients’ needs for these important therapies,” he added.

Lonza, which has previously set up similar sites in the United States and Singapore, will build and operate the infrastructure, the companies said. A spokesman with Sanofi said 200 jobs would be created in the process.

Sanofi, which has failed to land two big biotech acquisitions over the past year, had said it would look to strike new partnerships to spur more growth for the company.

The French group is also open to more asset swaps after agreeing to hand its animal health unit to Boehringer Ingelheim in exchange for the German company’s consumer healthcare operations last year.

Lonza, which reported higher annual profits in January, has also said it was keen to expand its global cell-biology portfolio.


Comments

Readers are required to have a valid Facebook account to comment on this story. We welcome your opinions to allow a healthy debate. We want our readers to be responsible while commenting and to consider how their views could be received by others. Please be polite and do not use swear words or crude or sexual language or defamatory words. FMT also holds the right to remove comments that violate the letter or spirit of the general commenting rules.

The views expressed in the contents are those of our users and do not necessarily reflect the views of FMT.

Comments